Intravitreous Ranibizumab Cost-Effective for Some With Proliferative Diabetic Retinopathy Intravitreous Ranibizumab Cost-Effective for Some With Proliferative Diabetic Retinopathy
At five years, intravitreous ranibizumab therapy for proliferative diabetic retinopathy (PDR) appears to be cost-effective relative to panretinal photocoagulation (PRP), but only in eyes with vision-impairing center-involved diabetic macular edema (CI-DME), according to new findings.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 6, 2019 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
Novartis nabs FDA priority review for potential eye blockbuster
If approved this will have the drugmaker go head to head against Roche ’s Lucentis and Regeneron’s Eylea (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - April 16, 2019 Category: Pharmaceuticals Source Type: news
Ranibizumab and Aflibercept Prompt Comparable Visual Gain in AMD Ranibizumab and Aflibercept Prompt Comparable Visual Gain in AMD
In patients with neovascular age-related macular degeneration (nAMD), aflibercept and ranibizumab achieve similar average visual acuity increases, according Australian researchers.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 31, 2019 Category: Consumer Health News Tags: Medscape Today News Source Type: news
Panretinal photocoagulation may increase diabetic macular oedema risk
Research, published inThe American Journal of Clinical Nutrition, suggests that treatment of proliferative diabetic retinopathy with panretinal photocoagulation, rather than ranibizumab injections, may increase the risk of diabetic macular oedema.Healio (Source: Society for Endocrinology)
Source: Society for Endocrinology - December 17, 2018 Category: Endocrinology Source Type: news
Genentech touts data for refillable eye implant in wet-AMD trial
Roche‘s (OTC:RHHBY) Genentech touted additional positive data last week from a Phase II study of its Port Delivery System, a refillable eye implant designed to deliver ranibizumab to treat wet age-related macular degeneration.
The company first reported top-line results from the Phase II Ladder study in July. The implant is intended to allow wet-AMD patients to go for months without needing to see an ophthalmologist for treatment; the current standard of care for wet-AMD patients involves monthly injections of therapy.
Get the full story at our sister site, Drug Delivery Business News.
The post Genentech touts da...
Source: Mass Device - October 29, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Optical/Ophthalmic Pharmaceuticals Wall Street Beat Genentech Roche Source Type: news
Two Treatments, Similar Outcomes in Diabetic Retinopathy
(MedPage Today) -- Visual acuity similar at 5 years with ranibizumab, photocoagulation (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - October 16, 2018 Category: Endocrinology Source Type: news
Avastin/Lucentis/Eylea ruling good news for patients, says RPS
Responding to news that the NHS will allow Avastin to be prescribed for age related wet macular degeneration, RPS President Ash Soni said:“This is a landmark ruling and good news for patients (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - September 21, 2018 Category: Drugs & Pharmacology Source Type: news
Implant Poised to Transform Macular Degeneration Treatment Implant Poised to Transform Macular Degeneration Treatment
A system that delivers ranibizumab without injections could be a turning point for patients with neovascular age-related macular degeneration, results from the highly anticipated LADDER trial show.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 27, 2018 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
Reminder: Invitation to Roche's Virtual Pipeline Event: Phase 2 LADDER results of the Port Delivery System (PDS) with Lucentis to be presented at the 2018 ASRS annual meeting
We are pleased to invite investors and analysts to participate in a live audio webcast and conference call on Thursday, 2 August 2018, featuring data from the Phase 2 LADDER study of the Port Delivery System (RPDS) with Lucentis to be presented at the American Society of Retina Specialists (ASRS) annual meeting (20-25 July 2018) in Vancouver, Canada. (Source: Roche Investor Update)
Source: Roche Investor Update - July 27, 2018 Category: Pharmaceuticals Source Type: news
